Addressing Optic Neuritis, Neuromyelitis Optica and Multiple Sclerosis

By promoting neuroprotection and remyelination

Promoting Neuroprotection

First-in-class SGK agonists for rare ophthalmological conditions


first-in-class small molecules promoting neuroprotection and remyelination.
Read more


Rare ophthalmological conditions: optic neuritis and neuromyelitis optica.
Read more


Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
Read more